VONTOBEL FINANCIAL PRODUCTS LTD. | Market Closed - Swiss Exchange 11:20:00 2024-06-28 EDT | ||
| 79 USD | -0.88% |
|
| Current month | -10.63% | ||
| 1 month | -11.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 79 | -0.88% |
| 24-06-27 | 79.7 | -3.63% |
| 24-06-26 | 82.7 | -2.13% |
| 24-06-24 | 84.5 | -0.24% |
| 24-06-20 | 84.7 | +1.19% |
Delayed Quote Swiss Exchange
Last update June 28, 2024 at 11:20 am
More quotesStatic data
| Product type | Certificats Divers |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| ZMRAAV | |
| ISIN | CH1166198270 |
| Date issued | 2022-03-24 |
| Maturity | 2027-03-24 (999 Days) |
| Parity | 0.18 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | les deux |
| Currency | USD |
Technical Indicators
| Highest since issue | 100.5 $ |
|---|---|
| Lowest since issue | 54.8 $ |
| Spread | 5 $ |
| Spread % | 0.63% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Certificates
- ZMRAAV Certificat
